Recombinant Human ITIH3 His-tag Protein, CF

2 μg/lane of Recombinant Human ITIH3 His-tag Protein (Catalog # 10427-IT) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at approximately 86 and 93 kDa under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ITIH3 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human ITIH3 is immobilized at 2 μg/mL (100 μL/well), the concentration of Recombinant Human TSG‑6 (Catalog # 2104-TS) that produces 50% of the optimal binding response is 1-10 μg/mL
• Source: Chinese Hamster Ovary cell line, CHO-derived human ITIH3 protein
  Ser34-Asp651, with a C-terminal 6-His tag
• Accession #: Q06033.2
• N-terminal Sequence: Ser34
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 70 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 81-98 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris and NaCl.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ITIH3 His-tag Protein, CF

• H3 polypeptide
• H3P
• inter-alpha (globulin) inhibitor H3
• inter-alpha (globulin) inhibitor, H3 polypeptide
• inter-alpha-inhibitor heavy chain 3
• inter-alpha-trypsin inhibitor heavy chain H3
• ITI heavy chain H3
• ITIH3
• ITI-HC3
• serum-derived hyaluronan-associated protein
• SHAP

Background

Inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3) is a heavy chain (HC) member of the ITIH family that is synthesized in the liver and circulates in the plasma (1). ITIH3 contains a signal sequence, propeptide, and a conserved von-Willebrand type A domain similar to other HCs in the family. The ITIH3 c-termini is trimmed to reveal a c-terminal aspartic acid residue that enables crosslinking of the HC to chondroitin sulfate (CS) (1,2). ITIH3 represents the single HC3 component of pre-a-trypsin inhibitor (PaI). PaI is a protease inhibitor involved in extracellular matrix stabilization that is composed of a single subunit of HC3 and bikunin, which are linked together via a CS moiety (1,3).  ITIH3 can alternatively be associated with hyaluronan (HA) to form the Serum-derived hyaluronan associated protein (SHAP)-hyaluronan (HA) complex known to assist in stabilizing HA-rich extracellular matrices in the context of inflammatory processes and ovulation (3,4). ITIH3 is up-regulated in acute inflammation via interleukins and PaI is considered a positive acute-phase protein (1,5). ITIH3 is implicated as a diagnostic and prognostic marker in several diseases including colorectal cancer (6), gastric cancer (7), pancreatic cancer (8), and Sjogrens's syndrome with rheumatoid arthritis (9). ITIH3 has been shown to increase cell attachment and reduce the number of metastases in an antitumoral role (10). Recombinant Human ITIH3 activity is measured though binding to Tumor necrosis factor-stimulated gene-6 (TSG-6). TSG-6 has high affinity for HC and plays an important role in the transfer of HC to HA matrix by forming a TSG-6:HC complex intermediate required for the transfer (4,11).

1. Salier, J.P. et al.(1996) Biochem. J. 315:1.
2. Bourguignon, J. et al. (1993) Eur. J. Biochem. 212:771.
3. Zhuo, L. et al. (2004) J. Biol. Chem. 279:38079.
4. Rugg. M.S. et al. (2005) J. Biol. Chem. 280:25674.
5. Daveau, M. et al. (1993) Biochem. J. 292:485.
6. Jiang, X. et al. (2019) Dis. Markers. 2019:5069614.
7. Chong, P.K. et al. (2010) J. Proteome Res. 9:3671.
8. Liu, X. et al. (2017) Br. J. Cancer 117:1846.
9. Liao, C.C. et al. (2016) J. Proteomics. 141:1.
10. Paris, S. et al. (2002) Int. J. Cancer 97:615.
11. Baranova, N.S et al. (2013) J. Biol. Chem. 288:29642.

Bioinformatics

• Uniprot:
  • Q06033.2()